So-Young finds beauty in growing economies of scale - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号)。如果该手机号尚未注册,将自动创建 FT中文网账号。短信可能需要几分钟送达,验证码15分钟内有效,请耐心等待:
请您阅读我们的用户注册协议和隐私权保护政策,点击下方按钮即视为您接受。
咏竹坊

So-Young finds beauty in growing economies of scale

The company’s revenue rose 33% in the second quarter, as aesthetic treatment services from its growing chain of self-operated clinics jumped 130%.
00:00

{"text":[[{"start":6.56,"text":"This article only represents the author's own views."}],[{"start":10.64,"text":"Cosmetic treatment provider So-Young International Inc. (SY.US) is quickly proving the old business truth that there’s beauty in economies of scale. The company wowed investors this week with a 10th straight quarter of triple-digit growth for the self-operated aesthetic treatment services that have become its core business since the pandemic."}],[{"start":32.837,"text":"On top of that, it also showed notably improving gross margins for the aesthetic treatment services, which it provides through its fast-growing network of self-branded centers. That network reached 65 centers by the end of June, up by 11 from three months earlier and more than double the 29 it had a year ago."}],[{"start":52.9,"text":"The centers are also showing a remarkable ability to achieve profitability very quickly. Of the 65 centers, 47 were profitable in the second quarter, while 51 achieved positive operating cash flow. So-Young is also leveraging those centers to sell cosmetic products to its customers through a partnership with a major manufacturer."}],[{"start":74.103,"text":"If there’s one small cloud in the company’s latest earnings report, released on Monday, it was So-Young’s forecast that its triple-digit revenue growth streak for the aesthetic treatment services business will come to an end in the current quarter. The company forecast that business would generate between 352 million yuan ($52.4 million) and 362 million yuan in the three months through September, which would be up 91.7% to 97.2%. But if there’s any downside to achieving economies of scale, it’s that growth rates inevitably slow as a company gets bigger, so we can’t fault So-Young too much on its inability to maintain triple-digit growth."}],[{"start":116.08,"text":"Investors didn’t seem to mind the imminent end of that streak either, with So-Young’s stock rising 21.3% the day of the results announcement."}],[{"start":125.137,"text":"So-Young’s stock was one of a small group we called “Chinese Easter eggs” last year, as investors suddenly took interest in their shares after years of neglect. So-Young’s was one of the best performers, as its shares rose sevenfold in the space of just a few weeks. But unlike most of those companies, whose shares later fell back to earth, So-Youngs’ stock has managed to retain some of its gains. The shares are still about triple from where they were before the rally that began in June last year, indicating genuine investor interest in the company’s ongoing transformation."}],[{"start":162.16,"text":"So-Young started out operating an online community for people interested in cosmetic surgery, earning most of its money from referral services from third-party clinic operators and product sellers. That business is extremely high margin, as its asset-light nature requires very little capital investment."}],[{"start":178.72,"text":"But So-Young also discovered the business comes with a big downside, namely, quality control. Quality varied widely among the many third-party clinic operators on the platform, exposing So-Young to reputational risk, as well as loss of customers when China embarked on periodic crackdowns on subpar clinics and product sellers."}],[{"start":198.948,"text":"The company discovered quality is much easier to control, and business is far more stable, when it operates its own clinics. It opened its first self-operated clinic at its headquarters in Beijing in August 2023, and has rapidly expanded the concept since then."}],[{"start":199.448,"text":"Eroding margins"}],[{"start":215.491,"text":"The biggest downside to the new business model is profit margins, which dropped rapidly due to the far higher costs of building and operating clinics compared with merely providing referral services. So-Young’s gross margin has fallen steadily over the last three years, dropping from 63.6% in 2023 to just 47.9% last year."}],[{"start":237.52,"text":"Officials said the company’s gross margin for aesthetic treatment services stood at just 28.1% in the second quarter, well below its overall gross margin of 44.1% for the quarter. But it also pointed out the latest treatment services gross margin improved by 3.8 percentage points from a year earlier, showing the treatment center business is becoming more profitable as it gains scale."}],[{"start":262.364,"text":"Most of the company’s major metrics reflect that improving efficiency that comes with growing scale. So-Young’s overall revenue rose 33.4% year-on-year to 505.2 million yuan in the second quarter from 378.7 million yuan a year earlier. But aesthetic treatment services grew by a far faster 129.5% year-on-year to 331.4 million yuan, expanding to two-thirds of total revenue from 38% a year earlier."}],[{"start":291.75,"text":"Revenue from its older information and reservation services fell 35% to 87.9 million yuan from 135.2 million yuan a year earlier, while sales of medical products and maintenance services fell 2.8% year-on-year to 73.9 million yuan."}],[{"start":308.463,"text":"Most of the metrics for its aesthetic treatment services tell a similar story of rapid scaling. Verified treatment service visits to its branded centers during the quarter rose 145% year-on-year to 165,200, while active users of its centers in the 12 months through June rose 154% to more than 255,300 from the previous 12-month period."}],[{"start":335.6,"text":"Significantly, the company said that about half of the new business to its clinic network came from referrals, reflecting its growing ability to attract new clients without heavy costs. Reflecting that, its sales and marketing expenses rose just 16.8% year-on-year during the quarter to 153.5 million yuan, far slower than its revenue growth rate, dropping sales and marketing expenses to 30% of its overall revenues from 35% a year earlier."}],[{"start":362.92,"text":"The company is also using its clinics to cross-sell products to customers through a partnership with Jinbo Bio-Pharmaceutical. It disclosed that one product from the partnership, Miracle Collagen, has sold over 66,000 units since its launch in April, while another, WeaveCol, launched in June, helps “fill the eye and midface areas while promoting ongoing collagen regeneration for a natural look.”"}],[{"start":387.28,"text":"The improving profitability metrics filtered down to So-Young’s bottom line, as its net loss narrowed to 22.7 million yuan from 36 million yuan a year earlier. “Looking ahead, we see a clear path toward profitability as our industry leadership solidifies and economies of scale continue to unfold,\" said CFO Shannon Shen."}],[{"start":405.36,"text":"The company hasn’t given specific targets for its new clinic openings for the next year, though it has said it will expand at a “measured pace,” while focusing on increased operational efficiency. That could be an important factor to watch, as overly aggressive expansion often undermines this type of brick-and-mortar service company if it starts to open outlets in less desirable locations simply to keep growing."}],[{"start":430.24,"text":""}]],"url":"https://audio.ftcn.net.cn/album/a_1788757853_9992.mp3"}

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

AI与通胀:央行行长该担忧到什么程度?

这取决于一个价值万亿美元问题的答案:AI是否真能带来预期的生产力提升?

印度企业界的乐观情绪站得住脚吗?

印度企业界公开表达的乐观情绪,与家庭和投资者的焦虑情绪之间的落差日益明显。

Lex专栏:中国药企在药品开发领域获得一席之地

外国制药集团如今开始购买中国本土开发创新药物的授权。

特斯拉与太空探索技术公司:以马斯克为中心的庞大企业星系

埃隆•马斯克旗下上市公司的合并有一定道理,但其他股东最终可能不如现在有影响力。

火箭、机器人和风险:马斯克的3.6万亿美元豪赌

全球首富试图促成迄今最大胆的一笔合并交易,但他还需要说服股东和全球监管机构。

埃博拉疫情扩散至西非,世卫组织发布警报

尼日利亚当局正紧急追踪一名本迪布焦型埃博拉病毒检测呈阳性者的数十名密切接触者。
设置字号×
最小
较小
默认
较大
最大
分享×